Table 4.

Multivariate associations between composite genetic risk for CFH Y402H rs1061170 and ARMS2 A69S rs10490924 and progression to overall advanced AMD, geographic atrophy, and neovascular disease among the AREDS combination antioxidant and zinc treatment compared to placebo

	Overall Advanced AMD			Geographic Atrophy			Neovascular Disease
	N=882/4124			N=485/4124			N=397/4124
Genetic risk group^a	HR (95% CI)^b	P- value^c	P- interaction^d	HR (95% CI)	P- value	P- interaction	HR (95% CI)	P-value	P- interaction
Low, low	0.32 (0.09–1.12)	0.075		0.55 (0.11–2.73)	0.466		0.15 (0.02–1.11)	0.063

Low, high	0.52 (0.28–0.94)	0.031	0.473	0.86 (0.34–2.17)	0.748	0.605	0.32 (0.15–0.70)	0.004	0.467

High, low	1.23 (0.82–1.85)	0.326	0.039	1.01 (0.59–1.75)	0.961	0.467	1.54 (0.85–2.78)	0.154	0.024

High, high	0.81 (0.62–1.05)	0.12	0.161	0.99 (0.69–1.43)	0.960	0.490	0.65 (0.44–0.95)	0.026	0.161

Genetic risk groups based on number of risk alleles for CFH Y402H rs1061170 and ARMS2 A69S rs10490924: low, low = 0 risk alleles for CFH and 0 risk alleles for ARMS2; low, high = 0 risk alleles for CFH and 1 or 2 risk alleles for ARMS2; high, low = 1 or 2 risk alleles for CFH and 0 risk alleles for ARMS2; and high, high = 1 or 2 risk alleles for CFH and 1 or 2 risk alleles for ARMS2.

Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by multivariate Cox proportional hazards models using the individual eye as the unit of analysis. All models are adjusted for age, sex, education, smoking status, body mass index, baseline AMD grade, and baseline drusen size.

P value reports the difference in the effectiveness of antioxidant and zinc treatment compared to placebo for each genetic risk group.

P interaction reports the difference in the effectiveness of the antioxidant and zinc treatment compared to placebo for each genetic risk group compared to the low, low genetic risk group